Business Context and Reporting Period
This Form 8-K was filed by Actinium Pharmaceuticals, Inc. on September 12, 2013, reporting events that occurred on September 9, 2013. The filing details corporate governance actions taken by the Board of Directors regarding employee compensation and equity incentives.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the approval of new equity plans.
Material Changes
The Board of Directors approved two new equity incentive programs effective September 9, 2013:
- 2013 Stock Plan: Approved for grants to employees, directors, and consultants. The plan expires on September 9, 2023, with a total of 2,750,000 shares of common stock available for grant.
- 2013 Equity Incentive Plan: Approved for grants to employees, directors, and consultants. The plan expires on September 9, 2023, with a total of 450,000 shares of common stock available for grant.
Guidance, Outlook, and Risks
The filing does not provide financial guidance, management commentary on future outlook, or specific risk factors. The primary disclosure relates to the potential dilution of existing shareholders due to the authorization of 3,200,000 total shares (2,750,000 + 450,000) for future grants under the new plans.
Investor Verification Checklist
- Verify the total number of shares authorized for grant (3,200,000) against the company's current outstanding share count to assess potential dilution.
- Review the attached Exhibits 10.1 through 10.4 for specific vesting schedules, exercise prices, and eligibility criteria for the new plans.
- Confirm the roles of Sergio Traversa as Interim President, Interim CEO, and Interim CFO, as noted in the signature block.